摘要
目的探讨双联抗血小板治疗脑梗死急性期的安全性和有效性。方法选择医院首次诊断为急性脑梗死的患者300例,采用随机数字表法分为对照组和观察组,各150例。对照组采用阿司匹林肠溶片200 mg,1次/天;观察组应用口服阿司匹林肠溶片100 mg,1次/天,同时口服硫酸氢氯吡格雷片75 mg,1次/天,连续服用21 d停服氯吡格雷,仅口服阿司匹林。两组患者治疗时间均为4周。结果治疗后,两组患者血清C反应蛋白水平较治疗前降低,且观察组改善更明显(P<0.05);两组患者的神经功能缺损程度(NIHSS)评分较治疗前降低,且观察组明显低于对照组(P<0.05);观察组治疗总有效率为86.00%,明显高于对照组的76.67%(P<0.05);两组不良反应发生率比较无明显差异(4.00%比2.00%,P>0.05)。结论双联抗血小板治疗急性期脑梗死安全性相似,但有效性更好,值得临床推广。
Objective To investigate the clinical safety and effectiveness of dual antiplatelet therapy in treating acute cerebral infarction.Methods A total of 300 patients firstly diagnosed as acute cerebral infarction admitted to our hospital were divided into the control group and the observation group by the random number method,150 cases in each group. The control group was given 200 mg Aspirin Enteric-Coated Tablets,1 time/d,while the observation group was given 100 mg Aspirin Enteric-Coated Tablets,1 time/d,and 75 mg Clopidogrel Hydrogen Sulphate Tablets,1 time/d. After 21 days of continuous use of the two drugs,only Aspirin Enteric-Coated Tablets were taken. The two groups were treated for 4 weeks. Results After treatment, the levels of serum C-reactive protein in the two groups were significantly lower than those before treatment, and the improvement in the observation group was more obvious（ P〈0. 05）, After treatment, the NIHSS scores in the two groups were significantly lower than those before treatment, and the observation group was significantly lower than the control group（ P〈0. 05）. The total effective rate of the observation group was 86. 00%, which was significantly higher than 76. 67% of the control group（ P〈0. 05）. There was no difference in the incidence rate of adverse reactions between the two groups（ 4. 00% vs 2. 00%, P〈0. 05）. Conclusion Dual antiplatelet therapy for treating acute cerebral infarction has similar safety and better effectiveness,it is worthy of clinical promotion.
作者
罗秋华
张蓓
Luo Qiuhua Zhang Bei(Department of Neurology, The Second People＇s Hospital of Sichuan, Chengdu, Sichuan, China 610017)
出处
《中国药业》
CAS
2017年第17期37-39,共3页
China Pharmaceuticals
关键词
双联抗血小板
脑梗死急性期
安全性
有效性
dual antiplatelet therapy
acute cerebral infarction
safety
effectiveness
